ATE366806T1 - Dna-molekül, herstellung und verwendung in der gentherapie - Google Patents

Dna-molekül, herstellung und verwendung in der gentherapie

Info

Publication number
ATE366806T1
ATE366806T1 AT96904886T AT96904886T ATE366806T1 AT E366806 T1 ATE366806 T1 AT E366806T1 AT 96904886 T AT96904886 T AT 96904886T AT 96904886 T AT96904886 T AT 96904886T AT E366806 T1 ATE366806 T1 AT E366806T1
Authority
AT
Austria
Prior art keywords
production
gene therapy
dna molecule
genes
interest
Prior art date
Application number
AT96904886T
Other languages
English (en)
Inventor
Beatrice Cameron
Joel Crouzet
Anne-Marie Darquet
Daniel Scherman
Pierre Wils
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366806(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE366806T1 publication Critical patent/ATE366806T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT96904886T 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie ATE366806T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9502117A FR2731014B1 (fr) 1995-02-23 1995-02-23 Molecules d'adn, preparation et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ATE366806T1 true ATE366806T1 (de) 2007-08-15

Family

ID=9476445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96904886T ATE366806T1 (de) 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie

Country Status (19)

Country Link
US (3) US6143530A (de)
EP (1) EP0815214B1 (de)
JP (1) JPH11500618A (de)
KR (1) KR19980702406A (de)
AT (1) ATE366806T1 (de)
AU (1) AU709111B2 (de)
BR (1) BR9607273A (de)
CA (1) CA2211427C (de)
CZ (1) CZ266897A3 (de)
DE (1) DE69637156T2 (de)
FI (1) FI973467L (de)
FR (1) FR2731014B1 (de)
HU (1) HUP9801216A3 (de)
IL (1) IL117214A0 (de)
MX (1) MX9706109A (de)
NO (1) NO973838L (de)
SK (1) SK114397A3 (de)
WO (1) WO1996026270A1 (de)
ZA (1) ZA961484B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
DE69836092T2 (de) 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
FR2776669B1 (fr) * 1998-03-24 2001-06-15 Rhone Poulenc Rorer Sa Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
IL138624A0 (en) * 1998-03-24 2001-10-31 Aventis Pharma Sa Nucleic acid transfer vectors, compositions containing same and uses
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
EP1165813A2 (de) 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Lineare und zirkuläre expressionselemente
US6746870B1 (en) * 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
DE19941186A1 (de) * 1999-08-30 2001-03-01 Peter Droege Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
WO2001049316A2 (fr) * 1999-12-30 2001-07-12 Aventis Pharma S.A. Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
CN1446258B (zh) * 2000-05-26 2013-01-09 艾文蒂斯药品公司 用固定化的寡核苷酸纯化三股螺旋体结构
BR0112633A (pt) * 2000-07-21 2003-09-16 Us Agriculture Método para substituir, translocar e empilhar dna em genomas eucarióticos
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
MXPA03008642A (es) * 2001-03-23 2004-06-30 Gencell Sa Metodos de purificacion y de deteccion de secuencias objetivo de adn de doble hebra mediante interaccion de triple helice.
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
US7138267B1 (en) 2001-04-04 2006-11-21 Epicentre Technologies Corporation Methods and compositions for amplifying DNA clone copy number
WO2002083889A2 (en) * 2001-04-10 2002-10-24 Imperial College Innovations Limited Methods for the production of minicircles
GB0108968D0 (en) * 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
JP4489424B2 (ja) * 2001-05-30 2010-06-23 グラクソ グループ リミテッド 染色体に基くプラットホーム
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US20030108524A1 (en) * 2001-10-18 2003-06-12 Melissa Diagana Vectors for expressing multiple transgenes
CN1671836B (zh) 2002-06-18 2012-02-08 卫材R&D管理有限公司 用于基因治疗的原代培养脂肪细胞
EP2801614B1 (de) 2002-08-29 2019-05-15 The Board of Trustees of the Leland Stanford Junior University Zirkuläre Nukleinsäurevektoren sowie Verfahren zur Herstellung und Verwendung davon
US7314746B2 (en) 2002-09-13 2008-01-01 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
US20040166512A1 (en) * 2002-11-12 2004-08-26 Kahn Michael L. Method for cloning PCR products without restriction or ligation enzymes
AT412400B (de) 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
ATE340264T1 (de) * 2003-06-10 2006-10-15 Mologen Ag Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
DE602004027538D1 (de) 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US20060046294A1 (en) * 2004-08-26 2006-03-02 The United States Of America, As Represented By The Secretary Of Agriculture Site-specific recombination systems for use in eukaryotic cells
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
EP1844142B1 (de) * 2005-01-20 2015-08-12 Nature Technology Corporation Vektoren und verfahren zur genetischen immunisierung
ATE545701T1 (de) * 2005-05-17 2012-03-15 Ozgene Pty Ltd Sequentielles klonierungssystem
MX2008009970A (es) * 2006-02-01 2008-11-19 Univ Johns Hopkins Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos.
EP2178896A1 (de) * 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptid-nukleinsäure-konjugat zur immunprophylaxe oder immuntherapie für neoplastische oder infektionskrankheiten
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
CN102083975A (zh) 2008-07-03 2011-06-01 利兰·斯坦福青年大学托管委员会 小环dna载体制剂及其制备方法和使用方法
WO2011057825A1 (en) 2009-11-16 2011-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Induction of gene expression in arthropods
DE102009054265A1 (de) 2009-11-16 2011-05-26 Giese, Matthias, Dr. Orale Verabreichung von DNA an Insekten
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
GB201307075D0 (en) 2013-04-19 2013-05-29 Mayrhofer Peter Plasmid for minicircle production
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
WO2021055760A1 (en) 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028530A (en) * 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
NZ225470A (en) * 1987-07-21 1990-06-26 Du Pont Stable and viable recombinant viral vectors
FR2631634B1 (fr) * 1988-05-18 1991-06-14 Centre Nat Rech Scient Vecteurs de clonage et d'expression dans une souche d'actinomycete, procede de transformation de cette souche, souche d'actynomycete obtenue et preparation de proteines
US5227288A (en) * 1990-10-01 1993-07-13 Blattner Frederick R DNA sequencing vector with reversible insert
EP0656941B1 (de) * 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
US5401632A (en) * 1992-07-16 1995-03-28 Wisconsin Alumni Research Foundation Triple helix purification and sequencing
WO1994009127A2 (en) * 1992-10-16 1994-04-28 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Supercoiled minicircle dna as as a unitary promoter vector
DE19502584C2 (de) * 1994-01-28 1999-08-12 Medigene Ag Ges Fuer Molekular Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
FR2715940B1 (fr) * 1994-02-10 1996-04-26 Pasteur Merieux Serums Vacc Procédé de préparation d'une banque multicombinatoire de vecteurs d'expression de gènes d'anticorps, banque et systèmes d'expression d'anticorps "coliclonaux" obtenus.
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique

Also Published As

Publication number Publication date
EP0815214A1 (de) 1998-01-07
JPH11500618A (ja) 1999-01-19
NO973838D0 (no) 1997-08-20
WO1996026270A1 (fr) 1996-08-29
EP0815214B1 (de) 2007-07-11
CZ266897A3 (en) 1997-11-12
DE69637156D1 (de) 2007-08-23
FI973467A7 (fi) 1997-08-22
FR2731014B1 (fr) 1997-03-28
ZA961484B (en) 1996-08-28
CA2211427A1 (fr) 1996-08-29
DE69637156T2 (de) 2008-02-07
FI973467A0 (fi) 1997-08-22
KR19980702406A (ko) 1998-07-15
HUP9801216A3 (en) 2001-08-28
AU709111B2 (en) 1999-08-19
IL117214A0 (en) 1996-06-18
AU4882296A (en) 1996-09-11
CA2211427C (fr) 2010-12-14
FI973467L (fi) 1997-08-22
HUP9801216A2 (hu) 1998-08-28
BR9607273A (pt) 1998-07-21
FR2731014A1 (fr) 1996-08-30
NO973838L (no) 1997-10-13
SK114397A3 (en) 1998-02-04
MX9706109A (es) 1997-11-29
US6143530A (en) 2000-11-07
US6492164B1 (en) 2002-12-10
US20030104444A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
ATE466960T1 (de) Verwendung von nukleinsäureliganden in der durchflusszytometrie
WO2001002568A3 (en) Human genes and gene expression products
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
DE69128893D1 (de) Genetische veränderung von endothelzellen
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
DE69534855D1 (de) Enzymaktive dna moleküle
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
ATE204481T1 (de) Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen
ATE208821T1 (de) Klonierung und expression von genen, kodierend für enzyme aus pilzen, die arabinan abbauen
DE69532485D1 (de) Trehalose-freisetzendes Enzym, dafür kodierende DNA, Herstellung und Verwendung
DK0877758T3 (da) Oprenset SR-p70-protein
DE69931759D1 (de) Methode zur erstellung von genexpressionsprofilen
DE69828654D1 (de) Isolierung und Verwendung von Nukleinsäuremolekülen, welche für Mitglieder der SSX-Familie kodieren
ATE301721T1 (de) In vivo herstellung von replicativen molekülen
EP1124840A4 (de) Ovarspezifische gene und proteine
DE19983297T1 (de) Gene, die für beta-Agarasen kodieren, und ihre Verwendung zur Herstellung von Enzymen für den biologischen Abbau von Agar
WO2001098350A3 (en) Compositions comprising net-4 modulations and their use for treating neoplastic disease
MX9709596A (es) Adn catal ??tico.
BR9810643A (pt) Genes e proteìnas de telomerase de vertebrado, eutilização dos mesmos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties